Otezla is the leading treatment in the post-topical, pre-biologic segment in its approved indications. Otezla is currently approved for three indications in the U.S. — the treatment of patients with moderate-to-severe plaque psoriasis who are candidates for phototherapy or systemic therapy; adult patients with active psoriatic arthritis; and adult patients with oral ulcers associated with Behçet's Disease. Otezla has patent exclusivity through at least 2028 in the U.S.
Otezla offers many benefits including:
- A strong strategic fit with Amgen's expertise in psoriasis and inflammation
- A differentiated, oral therapy complementary to Amgen's existing inflammation franchise of innovative biologics and biosimilar products
- Acceleration of Amgen's near- and long-term growth
Sales of Otezla in 2019 were $1.6 billion driven by strong volume growth. Amgen is focused on medicines that can deliver sustained, long-term volume driven growth and the Company believes there is a substantial opportunity to grow Otezla through global expansion and new indications!
Bringing Innovative Medicines to Patients -- The number of patients suffering from chronic inflammatory diseases is growing worldwide. Amgen is a leader in this very large therapeutic category. Otezla is positioned as a therapy of first-choice in patients with moderate-to-severe psoriasis who are not satisfied with topical therapies given its differentiated mechanism of action and established efficacy and safety profile. In psoriatic arthritis, Otezla is positioned for use in patients early in their disease and/or with moderate joint involvement.
Expansive Geographic Reach -- Otezla is approved in 54 countries, including major markets such as France, Germany and Japan. Amgen is well positioned to continue driving Otezla international sales growth!
The Marketing Manager will lead the implementation of Otezla brand strategy, including creative development of marketing materials to support the Otezla sales force, non-personal communication, and peer to peer tactical implementation. In addition, this individual will deliver planning and delivery of sales force meetings, collaborate in development of brand-building marketing plans and support tactics to accelerate Otezla growth.
The person in this role will partner with the Inflammation Nephrology Business Unit (INBU) matrix teams and key cross-functional partners when working on key brand projects.
This position will consist of agency and vendor management, as well as matrix management across Amgen’s commercial, medical, legal, and regulatory enterprises.